Biphasic vasodilator action of troglitazone on the renal microcirculation

Journal of the American Society of Nephrology

Volumn 13, Issue 2, 2002, Pages 342-349

  Arima, Shuji ^a   Kohagura, Kentaro ^a   Takeuchi, Kazuhisa ^a   Taniyama, Yoshihiro ^a   Sugawara, Akira ^a   Ikeda, Yukio ^a   Abe, Michiaki ^a   Omata, Ken ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN; CALCIUM CHANNEL BLOCKING AGENT; NORADRENALIN; TROGLITAZONE; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; GLOMERULUS; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASOCONSTRICTION; VASODILATATION;

EID: 0036154243     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance
2. Insulin resistance in essential hypertension
3. Role of insulin resistance in human disease
4. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers
5. Mechanisms and clinical effects of thiazolidinediones
6. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
7. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
8. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus
9. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats
10. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats
11. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
12. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect
13. 2+ currents and endothelial nitric oxide production
14. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery
15. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
16. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
17. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
18. Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole
19. Endotheliumderived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole
20. Diverse effects of calcium antagonists on the glomerular hemodynamics
21. High glucose augments angiotensin II action by inhibiting NO synthesis in in vitro microperfused rabbit afferent arterioles
22. Troglitazone (CS-045), a new antidiabetic drug
23. Removal of endothelium dependent relaxation by antibody and complement in afferent arterioles
24. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry
25. Elevated renovascular tone in young spontaneously hypertensive rats: Role of cytochrome P-450
26. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies
27. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
28. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects
29. Insulin mediated skeletal muscle vasodilation is NO dependent: A novel action of insulin to increase NO release
30. NO release accounts for insulin's vascular effects in humans
31. Effects of pioglitazone on vascular reactivity in vivo and in vitro
32. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
33. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro
34. The effects of alpha tocopherol supplementation on monocyte function
35. Juxtamedullary microvascular dysfunction during the hyperfiltration stage of diabetes mellitus
36. Divergent effects of KC1-induced depolarization on afferent and efferent arterioles
37. 2+] in renal arterioles
38. An antidiabetic thiazolidinedione is high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ)
39. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells
40. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
41. Expression and function of PPARγ in rat and human vascular smooth muscle cells
42. 2 is a ligand for the adipocyte determination factor PPAR γ
43. Biphasic vasodilator action of troglitazone on the renal microcirculation
44. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
45. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients
46. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
47. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells